Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2024 call → NOWe need to determine if management describes that successive engagements of the same kind are coming in at progressively larger size. The question asks about a specific phenomenon: the unit size of the company's own repeatable business is escalating, with comparison to its own past, already real and recurring, and early (not yet fully reflected in results). Let's review the transcript. The call covers Copart's Q1 2024 earnings. Management discusses various segments: insurance, Blue Car, dealer, international, specialty equipment, Purple Wave investment, etc. Key points: - Insurance volumes up 9.7% year-over-year, but total loss frequency still below historical norms. They expect recovery. - Blue Car (bank, finance, fleet, rental) grew over 35% year-over-year. - Dealer sales volume up 13%. - International unit growth over 24%. - They mention investments and partnerships. Does management convey that the size of individual deals, contracts, customers, or programs is escalating? They talk about growth in volumes, but not about the size of individual engagements. For example, they don't say "our new contracts are larger than before" or "customers are starting with bigger commitments." They mention growth in unit counts, but that's volume, not unit size. They also discuss Purple Wave investment, but that's an acquisition, not a repeatable business engagement. They talk about strategic partnerships, but not about escalating size of deals. The question specifically asks about "successive engagements of the same kind" coming in at progressively larger size. There is no such description. Management talks about growth in volumes, market share, and expansion, but not about the individual size of orders or contracts increasing. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.